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journal homepage: http://www.elsevier.com/locate/crvasaPreamble. It is a great honor to be invited by the Czech Society
of Cardiology to act as the guest editor of this special Cor et
Vasa issue focused on acute coronary syndromes. Instead of
the traditional opening editorial I decided to present a very
interesting international discussion, which followed the
publication of the provocative Czech position paper on acute
coronary syndromes a year ago [1].
The original comments of distinguished international
experts are presented below as their reaction on the Czech
position statement. These comments were originally sent to
me in the form of private e-mail communication. All
colleagues cited below in the article approved the publication
of their comments in this editorial article.
Introduction
The European Society of Cardiology (ESC) guidelines deﬁne
acute coronary syndromes (ACS) based on their pathophysiol-
ogy: ‘‘ACS in their clinical presentations share a widely
common pathophysiological substrate. Pathological, imaging,
and biological observations have demonstrated that athero-
sclerotic plaque rupture or erosion, with differing degrees of
superimposed thrombosis and distal embolization, resulting
in myocardial underperfusion, form the basic pathophysio-
logical mechanisms in most conditions of ACS.’’ The classiﬁ-
cation of ACS is based on the electrocardiogram (ECG). Two
categories of patients may be encountered: (1) Patients with
acute chest pain and persistent (>20 min) ST-segment eleva-
tion. (2) Patients with acute chest pain but without persistent
ST-segment elevation [2].
It is surprising that there is a detailed universal deﬁnition
of acute myocardial infarction [3], but similar deﬁnition does
not exists for acute coronary syndrome. In classical terms,
acute coronary syndromes include ST-elevation myocardial
infarction (STEMI), non-ST elevation myocardial infarction
(non-STEMI) and unstable angina pectoris (UAP). Thus, the
deﬁnition of acute coronary syndrome should include the
universal deﬁnition of myocardial infarction plus deﬁnition of
unstable angina pectoris. And here is the key problem, today
thanks to precise troponin measurements the group ofpatients classiﬁed as UAP includes two entirely different
populations: (a) patients with signiﬁcant coronary artery
disease and unstable plaques causing chest pain, versus (b)
patients with chest pain caused by non-coronary (and
frequently even non-cardiac) problems. This problem is
reﬂected in results of some large clinical trials – e.g. in the
TRILOGY trial [4], showing different results for patients
having their ACS conﬁrmed by coronary angiography (prasu-
grel was effective in these patients) and for patients without
such conﬁrmation (prasugrel was ineffective in this subgroup,
most likely due to the fact that some of these patients might
suffer from other diseases, not related to thrombotic coronary
obstruction).
The Czech Society of Cardiology published in 2013 a
position statement [1] demonstrating some important limita-
tions of the current classiﬁcation and opening the question
whether the above mentioned current classiﬁcation of acute
coronary syndromes (ACS) is still practical or whether it should
be replaced by an updated one. This provocative article
stimulated an interesting international discussion among
experts from many countries. The summary of this discussion
is presented below.
The summary of the Czech proposal for classiﬁcation of
acute coronary syndromes [1] is mentioned below:
(a) Acute coronary syndrome with ongoing myocardial ische-
mia (OMI) is deﬁned as ongoing (or recurrent) clinical signs of
acute myocardial ischemia (i.e. persistent chest pain and/or
dyspnea at rest) plus at least one of the following:
1. ST segment elevations in ≥2 consecutive ECG leads
(≥2 mm for leads V2–V3, ≥0.5 mm for leads V7–V9 and
≥1 mm for other leads).
2. New onset bundle branch block (right or left).
3. Persistent ST segment depressions in ≥2 consecutive
ECG leads (≥2 mm for chest leads and ≥1 mm for
extremity leads).
4. Cardiogenic shock or ‘‘pre-shock’’ type of hemodynamic
instability (low-to-normal blood pressure + tachycardia
+ cool extremities) due to suspected ischemia.
5. Malignant arrhythmias including resuscitated cardiac
arrest with return of spontaneous circulation.
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7. New onset of a wall motion abnormality on cardiac
imaging.
(b) Acute coronary syndrome without ongoing myocardial
ischemia (OMI) includes all other acute coronary syn-
dromes. Speciﬁcally, these are patients with unstable
angina and with small acute myocardial infarction (tropo-
nin elevation) not having the above-mentioned signs of
ongoing ischemia at the time of ﬁrst medical contact.
For further details see the full text of the original position
statement [1].
We may face a new era in ACS diagnosis and this new era may
be featured by two important modiﬁcations:
1) The classiﬁcation of ACS needs update: either (a) unstable
angina may merge with stable angina [5] and/or the true
acute non-STEMI will merge with STEMI, or (b) ACS may be
classiﬁed based on the presence or absence of ongoing
myocardial ischemia (OMI) – the proposal is further discussed
below in details.
2) The name acute CORONARY syndrome should be used only
for patients with PROVEN CORONARY disease. In other
words, to establish the ﬁnal (not the working) diagnosis of
ACS patients they should have either (a) an old known
positive coronary angiography, or (b) a new – acute –
positive CAG or (c) at least a positive CT-coronary
angiography. This would eliminate false positive diagnoses
not only in trials, but also in clinical practice. Such approach
(need to know coronary anatomy before establishing the
ﬁnal diagnosis) may facilitate early differential diagnosis
with other illnesses (e.g. Tako-tsubo, acute myokarditis,
gastroesophageal reﬂux, etc.).
The international comments to the original position
statement paper [1] are grouped by their main message to
six sections: (1) supportive comments to the ‘‘OMI’’ classiﬁca-
tion, (2) comments considering the proposal not suitable for
many countries or regions, (3) request for more data to deﬁne
the high risk group and to conﬁrm the unstable angina pectoris
(UAP) disappearance, (4) similar system is already in place, (5)
change of classiﬁcation may be difﬁcult or impractical, and (6)
potential problems with differential diagnosis of other ill-
nesses.
Comments supporting the new ‘‘ACS–OMI’’
classiﬁcation
This is a very thoughtful article and I believe that in Hamilton,
Canada, we tend to follow this approach if feasible. Most
patients with STEMI and within 12 hrs within the city go
directly for primary PCI and those with non ST elevation ACS
+ ongoing symptoms or those at high risk (e.g. the TIMACS) are
sent if possible to the cath labs which operate 24/7. Patients
from longer distances (or referral area can extend to about
120 Kms) may follow this, although at time the local doctors
ﬁrst give thrombolysis and then transfer immediately only
those who appear to be unstable or those who have not
evidence of reperfusion. Non ST elevation MI patients who areunstable or high risk can also be transferred within 24 hrs.
Others may have stress testing after discharge and then get
referred or sometimes get referred without stress test. So in
our setting the principles that are outlined in your article are
generally followed taking into account distance and access.
(Salim Yusuf)
Our case from the last week supports your proposal without
further words: the reason we went to the cath lab was: the
patient still had pain! We have to do something for these
patients, frequently having left circumﬂex or even left main
lesions. (Menko-Jan DeBoer)
You have generated very robust and useful discussion on
this important issue! I too am supportive of this initiative of
addressing how to approach ACS deﬁnition and implications
for early angiography. (Chris Granger)
This is an interesting and very pragmatic concept that
deserves further discussion and validation. I am very
supportive. (Jean-Pierre Bassand)
A selection of patients who present with non-STEMI should
be treated 'STEMI-like', which is also common practice in
many centers with 24/7 cath-facilities. The patients with left
circumﬂex or left main occlusion or ischemia often present
without ST elevation. A study randomizing this kind of high-
risk non-STEMI patients to early vs late intervention would be
unethical the moment the patient is still having chest pain or
other signs of ongoing ischemia. The question is what to do
with high-risk non-STEMI patients who present at a non-PCI
center or at centers without 24/7 cath-facilities. Send them
immediately to a PCI center? The recently presented and
published ELISA-3 trial addressed this issue and it might be
that patients presenting at a non-PCI center beneﬁt from early
intervention, although this was a subgroup analysis. To my
opinion, we should no longer focus on the presence or absence
of ST elevation as sole determinants of early angiography or
reperfusion therapy and completely agree with your concept.
(Arnoud van't Hof, comment shared by Jeroen Bax)
Very interesting new classiﬁcation, which seems to be more
close to our clinical needs. I run a single center registry in ACS
patients with long-term clinical follow-up and shall test the
impact of this new classiﬁcation on clinical outcome depend-
ing on the chosen strategy. (Kurt Huber)
I like this proposal a lot. That is exactly what we already do:
‘‘24/7’’ cath lab activation is not limited to ongoing ‘‘ECG’’
STEMI only because there are even more high risk patients
with other ECG patterns/clinical conditions. If I just take an
example of my last call 2 days ago: ST depression on V4–6, still
mild chest pain despite initial therapy, we did immediate
coronary angiography expecting ‘‘ECG-hidden’’ acute left
circumﬂex as culprit. Instead, it was subtotal distal trifurcating
left main combined with chronic total occlusion of the right
coronary artery! Immediate intraaortic balloon pump (IABP)
and urgent coronary artery bypass surgery (CABG), patient
survived and currently is already out of intensive care unit
(ICU). If this patient would enter non-PCI hospital, time-
consuming risk stratiﬁcation, long discussions about P2Y12
pretreatment, etc. . . .. . . You can imagine what would happen
by delaying time to right diagnosis (which can be established
in such case only by angiography). I think what you suggested
really is an ‘‘upgrade’’ of mature STEMI network to become
‘‘acute cardiac network’’. It is therefore not probably for
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tion of ‘‘STEMI network’’ to ‘‘acute cardiac network’’, it
becomes a new phase of the Stent for Life (SFL) project for
mature STEMI networks (and not for beginners). (Marko Noč)
I agree with you completely. (Deepak L. Bhatt)
The proposal is not suitable for many countries or
regions where thrombolysis is still widely used
Many thanks for sharing this interesting and provocative
proposal, which opens a necessary new debate regarding
management of non-STE ACS. Your proposal is really well
supported and very applicable to countries like the Czech
Republic, where there is an excellent and uniform network
for ACS management at a national level, which has
abolished thrombolysis. However, I think that it is not
applicable to the vast majority of countries, as most regional
networks for STEMI management still consider pharmaco-
invasive reperfusion with prehospital lysis as an alternative
to primary PCI when it is not available or cannot be
performed with an acceptable transfer delay. For instance,
in Spain the current percentage of lysis varies between 20
and 40% of total reperfusion treatments. (Francisco Fernandez
– Aviles)
The concept of new classiﬁcation reﬂects the reality and
potential needs in clinical practice of invasive treatment of
ACS. In Poland similarly to your country very high number of
cathlabs should enable timely interventions in STEMI and
very high risk NSTEMI (ACS with OMI) patients. Unfortunately
still the delays of primary PCI are substantial. Prehospital
thrombolysis is a solution in certain regions and circum-
stances. In many countries the delays are unavoidable and
prehospital thrombolysis is necessary. The proposed classiﬁ-
cation deﬁnitely warrants further debate. The results of
ongoing studies regarding the efﬁcacy and safety of very early
interventions in NSTEMI with OMI may support your
proposal. The role of prehospital ﬁbrinolysis (when unavoid-
able delays of PCI) in NSTEMI with OMI is still not clear.
Focusing early diagnosis in ACS on ongoing myocardial
ischemia (OMI) is a great value of your publication. (Andrzej
Budaj)
The message from Andrzej summarises my views too. I do
like the acronym OMI. It is useful. A good initiative Petr.
(Kenneth Dickstein)
The proposal is provocative, but the importance of deﬁning
ACS according to the initial ECG presentation still holds,
because the urgency of PCI is certain in the presence of STEMI,
while ‘‘to be deﬁned case-by-case’’ in NSTE-ACS. In addition,
thrombolysis is still an option in several areas of Europe, and I
think it would be confusing to have two overlapping
classiﬁcations running at the same time for the two different
therapeutic options. (Raffaele De Caterina)
Utilizing the concept of ‘‘ongoing ischemia’’ as a strategy-
driving factor is certainly very intuitive, reasonable, and
already applied in many countries/regions; however its
widespread applicability needs to be veriﬁed according to
local settings. In addition, your new classiﬁcation hints to new
guidelines, but for that we do need some hard outcome data.
(Germano Di Sciascio)Interesting concept which may well apply locally but not
in countries or regions that still use the pharmaco-invasive
strategy for some of our rural patients with longer transfer
times despite helicopter use. It is simply a matter of
geography including distance. The other issue relates to
the data suggesting that most patients with non-STE
ACS will not require primary PCI (the ABOARD trial) but
no one would argue about emergency angiography for
patients with persistent ongoing pain and/or ischemia
(Bernard Gersh)
I agree this is where the ACS is moving: further protocol-
driven rational management. Earlier intervention in the non-
STEMI population (‘‘should non-STEMI be treated like
STEMI’’) in appropriate patients is probably the next
paradigm. Indeed the DANCE trial in London has mobilised
ambulances for non-STEMI management along such lines
but it is difﬁcult to prove it is advantagous. Also as has been
suggested lysis is still being used worldwide (judging by the
responses we are getting to the STREAM trial). In some
systems (such as yours and ours) most if not all patients do
go to the PCI centre expeditiously, but clearly in others delays
can be incurred with worse outcomes. So taking on board all
the other comments I believe that (1) Groups 1–5 per your
classiﬁcation go straight to the cath lab anyway as per the
ESC Guidelines, (2) the others need to be assessed and
discussed. There is little evidence having said that for any
advantage for any of arrhythmic, ‘‘haemodynamically
unstable’’ acute non-STEMI to be taken urgently to the cath
lab, although that is what we do. I think the proposal misses
two real issues: (a) the use of thrombolysis world wide and
more importantly (b) there are patients who are not as hot as
you indicate but who wait for 24–72 hours for their cath
proceed. Giles Montalescot and myself are putting together a
trial to see whether ‘‘very warm’’ patients do better with
urgent intervention. I think it is fantastic that you have
started a debate. (Anthony Gershlick)
Unfortunately not all the countries are Czech Republic. In
my country (Italy), the latest nationwide data on the reperfusion
treatment are the ones below. Fibrinolysis is still used in about
60% of the patients in centres without cath lab, in 28% of the
cases in centres with cath lab available only in the working
hours; only in the centres with cath lab 24/7 the use of
ﬁbrinolysis is negligible (but anyway existing). It is very
important not to apply the beautiful data from the best STEMI
networks published in the literature to the ‘‘real world’’ STEMI
management in a whole country. Because ﬁbrinolysis is
applicable in STEMI but not in NSTEMI, the assumption of
the Czech colleagues is not applicable in my country. The
proposal could be applied in other countries, of course. (Marco
Tubaro)
You have shaked many trees. . .. In principal I agree, it may
be feasible in Belgium, but real life depends on geography.
(Jozef Bartunek)
More data are needed to deﬁne the high risk group
and the disappearance of unstable angina
I like your approach to early invasive treatment of non-STE
ACS. It will be important to obtain rigorous data that help to
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subject – the disappearance of unstable angina in the era of
high sensitivity (hs) troponins. (Eugene Braunwald)
This is very interesting and correct approach from the
pathophysiological point of view. Unfortunately, treatment
strategies are at this stage difﬁcult to match with this concept.
Together we should, however, consider to discard in the future
the diagnosis of ‘‘unstable angina’’, because with hs troponins
this is less justiﬁed. (Christian Hamm)
Your proposal merits full attention not only to the Czech
acute cardiac care providers but to a more international
platform as it is a clinical based approach that might facilitate
and streamline acute management of ACS patients. The
proposal implies a high PCI availability which is not
guaranteed in many regions. In addition, the main difference
in management will be in the group of patients that showed
ischemia on admission and will be sent in your proposal
directly to the cathlab, whereas in many situations non-STE
ischemia will disappear after 30–60 minutes of anti-anginal
drugs and those patients will got invasive evaluation 24–72 h
after admission. It might be interesting to study ﬁrst this
‘‘urgent invasive protocol’’ in this subpopulation. Your
proposal is also an opportunity to critical evaluate the current
ACS classiﬁcation and to compare the advantage and the
disadvantage of both classiﬁcations systems. (Marc Claeys)
I suspect we would all agree that the direction of travel is to
accelerate treatment for high-risk non-STEMIs (and indeed all
non-STE ACS cases). I think it is premature to consider losing the
STEMI/NSTEMI classiﬁcation. From responses there is still a lot
of work to do internationally to get systems of healthcare to
change to deliver timely primary PCI and pharmaco-invasive
processes are still clearly used. So, although these are
continuing challenges, the STEMI cohort in effect automatically
fulﬁls the OMI classiﬁcation. I suspect that most clinicians
would investigate late-presenter STEMI cases (who fall outside
of reperfusion windows) but who have on-going ischaemia at
the earliest opportunity. The main issue then is to identify those
non-STEMI cases where much earlier treatment provides
beneﬁt. Although any earlier treatment that minimises myo-
cardial damage may prove effective in the longer-term, this is
probably dependent on the degree of ischaemia, vulnerable
territory, potentially for harm during procedures etc. One could
argue that most non-STE ACS patients have ongoing ischaemia
when they present to ‘‘ﬁrst medical contact’’, but we do not yet
have sufﬁcient evidence to suggest a primary PCI-like strategy
for these cases. I personally am attracted to the ambulance
services triaging cases to primary PCI-capable centres such that
immediate, very early or next day angiography can be offered as
deemed appropriate depending on individual patient charac-
teristics. As long as the patient is in the right centre, the current
guidelines allow for this. TIMACS has had an impact on some
systems of care (but this is for earlier angiography – within
24 hours – rather than a primary PCI-like strategy), but many still
believe that you need more than one piece of evidence to start
changing national protocols. In many countries of course there
is no such thing as a national protocol, and it is up to individual
localities or regions to develop the most appropriate networks
and pathways of care, which they do with the appropriate steer
from the major international guideline groups. There are on-
going studies that will give us additional insight but I don't thinkany are powered to give us deﬁnitive answers as yet, so perhaps
Petr's challenge is really a challenge to set up such a deﬁnitive
large-scale international study. Sorting out the inclusion and
exclusion criteria would be key to a successful trial. (Mark
DeBelder)
Very interesting and provocative article. I do understand the
interesting concept that you put across in this article of
distinguishing ongoing myocardial ischaemia. I believe that
our previous biomarker detection systems were insufﬁciently
sensitive to identify some of the non-ST elevation myocardial
infarctions from within the ‘‘unstable angina’’ cohort. I think we
will be left with a small and heterogeneous number of ‘‘unstable
angina’’ diagnoses overlapping with other causes of ECG
abnormality – including non-cardiac causes. In my view it
would be critical to distinguish type 1 myocardial infarction from
type 2 (secondary causes for example following arrhythmia or
heart failure) as these have different therapeutic implications.
This distinction relies on the clinical context. The issue of
ongoing ‘‘myocardial ischaemia’’ is complex as it implies that
we can detect initial ischaemia and continuing ischaemia in all
of these patients – I think this will be challenging. I think you
have provoked a very interesting discussion and I am sure that a
lot of valuable ideas may come out of this! (Keith Fox)
I agree that this is a forward-looking proposal, very
interesting. Unfortunately, there is not as much data as I
would like on the status of chest pain at the time patients have
been taken to the cath lab versus treated medically in the prior
non-STE ACS trials. This is certainly intuitive however, and
future studies should collect this data. (Gregg Stone)
Similar system is already in place
Your concept is very much matching the needs of your country
and proﬁting from your experiences with even long distance
transports of STEMI patients to tertiary centres for primary PCI.
The logistic situation in Germany is very different. As you
know, we have a large number of 24/7 cath-labs in Germany, so
that any ACS should be directly admitted to those (STEMI-
patients directly into the cath-lab). In addition, the German
Cardiac Society has supported the implementation of chest
pain units (CPU) all over the country, the current number of
certiﬁed CPUs (certiﬁed by the German Cardiac Society) is 167
(see map of Germany with current CPU under http://cpu.dgk.
org/index.php?id=376). In the ideal setting, any patient with
ACS in Germany would be admitted to a hospital with PCI
facility, many of them with additional certiﬁed CPUs providing
the expertise to make rapid decisions also in patients with ACS
without persistent ST-elevations according to the risk stratiﬁ-
cation of current ESC guidelines. Taking these considerations
into account – at least in my view – your proposed new ACS
classiﬁcation would not help improving the current ACS-care
in Germany. (Anselm Gitt)
Change of classiﬁcation may be difﬁcult or
impractical
It is certainly an interesting concept. Practically it may be hard
to change all of the terminology with which people are so
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and non Q Wave to STEMI and NSTEMI. (David Holmes)
Conceptually a great and well described construct. Logisti-
cally may be hard to get people to change terminology.
(Kenneth Mahaffey)
I agree that it is a great idea to open a discussion on ACS
classiﬁcation and treatment strategy. In Denmark we are
lucky – like in your country we can provide PPCI and do not
use thrombolysis. Non-STEMI: we all agree that there is a
small subgroup with on-going ischaemia that should be
taken to cath acutely. The problem is how we handle the
remaining 90–95%. We have discussed your proposal in our
PCI team. The difﬁculty is to identify the high risk patients
among the remaining ACS patients and secondly whether
this high risk group will beneﬁt from immediate cath. We are
conducting a trial (NONSTEMI, principal investigator Chris-
tian Terkelsen) where high risk non-STEMI patients are
randomized to immediate cath vs cath within 24/72 hour
according to ESC guidelines. Personally after discussing
implementation of STEMI networks with colleagues in
many countries I realize that there are many different
barriers and obstacles. The message that STEMI patients
need urgent action is a simple one – the non-STEMI
algorithm is more complex and the evidence is not so
strong. It is important that we deliver simple messages to the
health care providers. However, an academic discussion on a
re-classiﬁcation of ACS is important and appropriate. (Steen
Dalby Kristensen)
The 2011 ESC non-STE ACS guidelines recommend
‘‘STEMI-like’’ management for very high-risk ACS patients
who may have an ‘‘evolving MI’’ (i.e., refractory angina, severe
heart failure, life-threatening ventricular arrhythmias, or
hemodynamic instability), regardless of ECG or biomarker
ﬁndings. I assume that ‘‘ongoing ischemia’’ (obviously in a
patient without STEMI) imply persistence of pain (and/or ECG
changes) following administration of standard initial treat-
ment (antiplatelets/anticoagulants  and if appropriate
nitrates and/or betablockers). In the Geneva area, the ﬁrst
medical contact for chest pain patients who do call an
ambulance is in the ﬁeld. A physician writes an ECG and, in
case of STEMI, activates an automatic alarm system (ALARME
STEMI) and the cath lab team is ‘‘automatically’’ called-in. For
the physician in the ﬁeld (usually a resident) it may be difﬁcult
to wait for the response to the ﬁrst treatment prior to decide
whether the patient has indeed ‘‘therapy refractory’’ ongoing
myocardial ischemia or not. This may lead either to an over-
use of our alarm system or a delay in the transport. (Marco
Rofﬁ)
I like the concept and agree that it should, if generally
implemented, improve outcome in patients with unrecog-
nized LCX occlusions. However, I am afraid that the positive
predictive value for groups 3–7 would be unacceptably low
and that it would lead to many false negative cath lab
activations and unnecessary shipping patients with prior MI
and heart failure. I deﬁnitely think that your great idea should
be tested prospectively in an observational study. (Stefan
James)
Since in Poland the thrombolytic treatment is almost
obsolete, your idea makes a lot of sense. It is simple, has
important practical implications and does not impact on theﬁnal diagnosis. As pointed out by many responders, it will be
difﬁcult to have it accepted by medical community. (Michal
Tendera)
Potential problems with differential diagnosis of
other illnesses
Interesting suggestion that needs discussion. However, ST-
Segment elevation may not always reﬂect ongoing ischemia.
Indeed, Tako-Tsubo patients have this feature even after signs
of ischemia have subsided clinically. We have now at least one
patient per week. (Thomas F. Lüscher)
Summary
This interesting international discussion demonstrated wide
variation of views. The current ACS classiﬁcation is widely
accepted and it is not certain whether it will undergo major
changes in near future. However, as many contributors to this
debate expressed, there are deﬁnite limitations and the new
proposal has the potential to overcome these limitations.
The author of this editorial believes, that the future
deﬁnition of acute coronary syndrome (as conﬁrmed, in-
hospital established diagnosis) should include knowledge of
coronary anatomy as conditio sine qua non for the ﬁnal
(discharge) diagnosis (coronary syndrome should have a prove of
coronary origin) and that the future classiﬁcation should
abandon the old separation between myocardial infarctions
with and without ST segment elevation (which is poorly
related to the severity of underlying disease and to clinical
outcomes).
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